艾德生物: 简式权益变动报告书

Core Viewpoint - The report outlines the equity change of Xiamen Ade Biological Pharmaceutical Technology Co., Ltd., indicating that Ningbo Yixiang Private Equity Investment Partnership (Limited Partnership) has reduced its shareholding to below 5% due to a series of share repurchases and dilutions [1][4][12]. Group 1: Company Information - Company Name: Xiamen Ade Biological Pharmaceutical Technology Co., Ltd. [1] - Stock Code: 300685, listed on Shenzhen Stock Exchange [1] - Address: No. 16, Cao'ejiang Road, Beilun District, Ningbo, Zhejiang Province [1][3]. Group 2: Shareholding Changes - Prior to the equity change, Ningbo Yixiang held 7,593,000 shares, representing 9.491250% of the total share capital [5][12]. - Following the changes, the shareholding decreased to 19,576,800 shares, which is 4.999998% of the total share capital [12]. - The reduction in shareholding was attributed to the company's share repurchase and dilution of shares due to new issuances [4][12]. Group 3: Future Plans - The company disclosed a reduction plan for shareholders holding more than 5% of shares, with Ningbo Yixiang planning to reduce its holdings from May 28, 2025 [4][12]. - As of the report date, there are no explicit plans for further increases or decreases in shareholding within the next 12 months, although the possibility remains [4][12]. Group 4: Legal Compliance - The report confirms compliance with relevant laws and regulations, including the Securities Law and the Management Measures for the Acquisition of Listed Companies [2][4]. - The information disclosure obligation has been fulfilled, ensuring no false records or misleading statements are present [2][15].